| Hazard Information | Back Directory | [Uses]
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo[1][2]. | [in vivo]
Plamotamab (0.17 mg/kg; i.p.) causes tumor growth suppression in human PBMC-engrafted mouse model containing Raji xenograft[2].
Plamotamab (0.3 mg/kg; i.p.) leads to cytokine release in cynomolgus monkeys, indicating a safety to be improved[2].
| [References]
[1] Parrondo RD, et al. Plamotamab (XmAb?13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742. DOI:10.1080/10428194.2021.2005045
[2] Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|